$171.57
-0.43 (-0.25%)
SAM News10 articles
AMSS Shares Surge on Good Twin Sales and $6.99M Convertible Deal
AMASS Brands shares surged following strong sales of its Good Twin organic non-alcoholic wine and a $6.99 million convertible funding deal. The stock remains volatile in its first week on Nasdaq.
Boston Scientific Plunges 3.4% on Cyberattack Disrupting Operations
Boston Scientific (BSX) shares dropped 3.4% after a global cyberattack disrupted order processing and shipping, erasing $2.5 billion in market value. Analysts estimate up to $369 million in Q3 revenue could be at risk.
Boston Scientific Plunges 4% on Cyberattack Revenue Warning
Boston Scientific shares dropped 4.1% after a cyberattack disrupted order processing and shipments, threatening up to $369 million in Q3 revenue.
Boston Scientific Rebounds 2% but Faces Headwinds as Week Closes Lower
Boston Scientific (BSX) climbed 2.03% to $50.37 on Friday, recovering 38% of Thursday's sharp decline. The stock still ended the week down 2.82% amid concerns over product demand and competition.
Boston Stock Falls as International Sales Counter US Cardiac Weakness
Boston Scientific shares fell 5.1% as strong international sales countered a US cardiac downturn. Q2 earnings beat estimates but guidance was cut.
Boston Scientific Tumbles 16% on Watchman Slowdown; Focus Shifts to Monday's Reaction
Boston Scientific shares fell 16.4% last week after CEO Michael Mahoney warned of declining Watchman usage and flat growth through Q3. Wells Fargo downgraded the stock and slashed its price target.
Boston Scientific Plunges to Two-Year Low on Watchman Slowdown
Boston Scientific shares fell 10% to a two-year low after CEO Michael Mahoney flagged slower use of its Watchman heart implant, raising growth concerns.
P&G's Gillette Commits $1 Billion to New Boston HQ Amid Growth Challenges
Procter & Gamble's Gillette brand is investing close to $1 billion to establish a new global headquarters and research hub in South Boston, maintaining its commercial and R&D presence in the city while shifting manufacturing to Andover in 2026.
Boston Scientific Stock Rebounds on Positive Farapulse Data, CHAMPION-AF Trial Looms
Boston Scientific shares recovered slightly after a recent sell-off, supported by new long-term data for its Farapulse ablation system. Investor focus now shifts to the upcoming CHAMPION-AF trial results expected in late March.
Boston Scientific Shares Extend Decline Amid Electrophysiology Concerns
Boston Scientific stock fell 2.6% in Monday trading, continuing last week's selloff as investors scrutinize the company's heart-rhythm device segment and Watchman demand.